Advertisement

Effect of Corticosteroids on Left Ventricular Function in Patients With Cardiac Sarcoidosis

      Cardiac sarcoidosis (CS) is an important cause of cardiomyopathy. The trajectory of left ventricular ejection fraction (LVEF) in patients with CS undergoing treatment remains unclear. Patients with CS who were treated with corticosteroids and who underwent transthoracic echocardiography were studied. Baseline characteristics, treatment, echocardiographic data (including baseline to follow-up change in LVEF), and outcomes were retrospectively evaluated. Among 100 patients, 55 had baseline reduced LVEF (<50%), and 45 had preserved LVEF (≥50%). At follow-up, 82% of patients demonstrated stable or improved LVEF. Change in LVEF was significantly higher in the baseline reduced than in the preserved LVEF group (5% [interquartile range 0 to 15] vs 0% [interquartile range −10% to 5%], p = 0.001). There was no difference in corticosteroid exposure or use of heart failure guideline-directed medical therapy between patients who did experience improvement in LVEF and those who did not experience improvement in LVEF. On multivariable analysis, baseline reduced LVEF (Odds ratio 54.89, 95% confidence interval 3.84 to 785.09, p = 0.003) and complete heart block (Odds ratio 28.88, 95% confidence interval 2.17 to 383.74, p = 0.011) at presentation were significantly associated with reduced LVEF after treatment. In conclusion, most patients with CS treated with corticosteroids maintain or improve LV systolic function. Cardiac characteristics at presentation impact prognosis in CS, despite treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Birnie DH
        • Nery PB
        • Ha AC
        • Beanlands RS.
        Cardiac sarcoidosis.
        J Am Coll Cardiol. 2016; 68: 411-421
        • Gilotra NA
        • Griffin JM
        • Pavlovic N
        • Houston BA
        • Chasler J
        • Goetz C
        • Chrispin J
        • Sharp M
        • Kasper EK
        • Chen ES
        • Blankstein R
        • Cooper LT
        • Joyce E
        • Sheikh FH
        Sarcoidosis-related cardiomyopathy: current knowledge, challenges, and future perspectives state-of-the-art review.
        J Card Fail. 2022; 28: 113-132
        • Yazaki Y
        • Isobe M
        • Hiroe M
        • Morimoto SI
        • Hiramitsu S
        • Nakano T
        • Izumi T
        • Sekiguchi M
        Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone.
        Am J Cardiol. 2001; 88: 1006-1010
        • Chiu CZ
        • Nakatani S
        • Zhang G
        • Tachibana T
        • Ohmori F
        • Yamagishi M
        • Kitakaze M
        • Tomoike H
        • Miyatake K.
        Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis.
        Am J Cardiol. 2005; 95: 143-146
        • Kandolin R
        • Lehtonen J
        • Airaksinen J
        • Vihinen T
        • Miettinen H
        • Ylitalo K
        • Kaikkonen K
        • Tuohinen S
        • Haataja P
        • Kerola T
        • Kokkonen J
        • Pelkonen M
        • Pietilä-Effati P
        • Utrianen S
        • Kupari M.
        Cardiac sarcoidosis: Epidemiology, characteristics, and outcome over 25 years in a nationwide study.
        Circulation. 2015; 131: 624-632
        • Sadek MM
        • Yung D
        • Birnie DH
        • Beanlands RS
        • Nery PB.
        Corticosteroid therapy for cardiac sarcoidosis: a systematic review.
        Can J Cardiol. 2013; 29: 1034-1041
        • Padala SK
        • Peaslee S
        • Sidhu MS
        • Steckman DA
        • Judson MA
        Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis.
        Int J Cardiol. 2017; 227: 565-570
        • Birnie DH
        • Sauer WH
        • Bogun F
        • Cooper JM
        • Culver DA
        • Duvernoy CS
        • Judson MA
        • Kron J
        • Mehta D
        • Cosedis Nielsen J
        • Patel AR
        • Ohe T
        • Raatikainen P
        • Soejima K
        HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.
        Heart Rhythm. 2014; 11: 1305-1323
        • Terasaki F
        • Yoshinaga K.
        New guidelines for diagnosis of cardiac sarcoidosis in Japan.
        Ann Nucl Cardiol. 2017; 3: 42-45
        • Kruse MJ
        • Kovell L
        • Kasper EK
        • Pomper MG
        • Moller DR
        • Solnes L
        • Chen ES
        • Schindler TH.
        Myocardial blood flow and inflammatory cardiac sarcoidosis.
        JACC Cardiovasc Imaging. 2017; 10: 157-167
        • Lang RM
        • Badano LP
        • Victor MA
        • Afilalo J
        • Armstrong A
        • Ernande L
        • Flachskampf FA
        • Foster E
        • Goldstein SA
        • Kuznetsova T
        • Lancellotti P
        • Muraru D
        • Picard MH
        • Retzschel ER
        • Rudski L
        • Spencer KT
        • Tsang W
        • Voigt JU.
        Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
        J Am Soc Echocardiogr. 2015; 28 (e14): 1-39
        • Nagueh SF
        • Appleton CP
        • Gillebert TC
        • Marino PN
        • Oh JK
        • Smiseth OA
        • Waggoner AD
        • Flachskampf FA
        • Pellikka PA
        • Evangelista A.
        Recommendations for the evaluation of left ventricular diastolic function by echocardiography.
        J Am Soc Echocardiogr. 2009; 22: 107-133
        • Nagueh SF
        • Smiseth OA
        • Appleton CP
        • Byrd BF
        • Dokainish H
        • Edvardsen T
        • Flachskampf FA
        • Gillebert TC
        • Klein AL
        • Lancellotti P
        • Marino P
        • Oh JK
        • Popescu BA
        • Waggoner AD.
        Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
        J Am Soc Echocardiogr. 2016; 29: 277-314
        • Rudski LG
        • Lai WW
        • Afilalo J
        • Hua L
        • Handschumacher MD
        • Chandrasekaran K
        • Solomon SD
        • Louie EK
        • Schiller NB.
        Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.
        J Am Soc Echocardiogr. 2010; 23: 685-788
      1. Caci HM. KWALLIS2: Stata module to perform Kruskal-Wallis test for equality of populations. Published online 1999. Available at: https://ideas.repec.org/c/boc/bocode/s379201.html. Accessed on June 16, 2021.

        • Shammas RL
        • Movahed A.
        Sarcoidosis of the heart.
        Clin Cardiol. 1993; 16: 462-472
        • Yasuchika K
        • Morimoto SI
        • Uemura A
        • Hiramitsu S
        • Ito T
        • Hishida H.
        Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block.
        Sarcoidosis Vasc Diffus Lung Dis. 2003; 20: 133-137
        • Nagai S
        • Yokomatsu T
        • Tanizawa K
        • Ikezoe K
        • Handa T
        • Ito Y
        • Ogino S
        • Izumi T.
        Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions.
        Intern Med. 2014; 53: 427-433
        • Griffin JM
        • Chasler J
        • Wand AL
        • Okada DR
        • Smith JN
        • Saad E
        • Tandri H
        • Chrispin J
        • Sharp M
        • Kasper EK
        • Chen ES
        • Gilotra NA.
        Management of cardiac sarcoidosis using mycophenolate mofetil as a steroid-sparing agent.
        J Card Fail. 2021; 27: 1348-1358
        • Gilotra NA
        • Wand AL
        • Pillarisetty A
        • Devraj M
        • Pavlovic N
        • Ahmed S
        • Saad E
        • Solnes L
        • Garcia C
        • Okada DR
        • Constantinescu F
        • Mohammed SF
        • Griffin JM
        • Kasper EK
        • Chen ES
        • Sheikh FH.
        Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience.
        J Card Fail. 2021; 27: 83-91
        • Birnie D
        • Beanlands RSB
        • Nery P
        • Aaron SD
        • Culver DA
        • DeKemp RA
        • Gula L
        • Ha A
        • Healey JS
        • Inoue Y
        • Judson MA
        • Juneau D
        • Kusano K
        • Quinn R
        • Rivard L
        • Toma M
        • Varnava A
        • Wells G
        • Wickremasinghe M
        • Kron J
        Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS− RCT).
        Am Heart J. 2020; 220: 246-252
        • Okada DR
        • Saad E
        • Wand AL
        • Griffin JM
        • Kasper EK
        • Chen EH
        • Chrispin J
        • Tandri H
        • Solnes LB
        • Gilotra NA.
        Effect of corticosteroid dose and duration on 18-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis.
        JACC Cardiovasc Imaging. 2020; 13: 1280-1282
        • Judson MA
        • Chaudhry H
        • Louis A
        • Lee K
        • Yucel R.
        The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis.
        Respir Med. 2015; 109: 526-531
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • Butler J
        • Casey DE
        • Colvin MM
        • Drazner MH
        • Filippatos GS
        • Fonarow GC
        • Givertz MM
        • Hollenberg SM
        • Lindenfeld JA
        • Masoudi FA
        • McBride PE
        • Peterson PN
        • Stevenson LW
        • Westlake C.
        2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America.
        Circulation. 2017; 136: e137-e161
        • Greene SJ
        • Butler J
        • Albert NM
        • DeVore AD
        • Sharma PP
        • Duffy CI
        • Hill CL
        • McCague K
        • Mi X
        • Patterson JH
        • Spertus JA
        • Thomas L
        • Williams FB
        • Hernandez AF
        • Fonarow GC.
        Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.
        J Am Coll Cardiol. 2018; 72: 351-366
        • Rybicki BA
        • Major M
        • Popovich J
        • Maliarik MJ
        • Iannuzzi MC.
        Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.
        Am J Epidemiol. 1997; 145: 234-241
        • Baughman RP
        • Teirstein AS
        • Judson MA
        • Rossman MD
        • Yeager H
        • Bresnitz EA
        • DePalo L
        • Hunninghake G
        • Iannuzzi MC
        • Johns CJ
        • McLennan G
        • Moller DR
        • Newman LS
        • Rabin DL
        • Rose C
        • Rybicki B
        • Weinberger SE
        • Terrin ML
        • Knatterud GL
        • Cherniak R
        Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis.
        Am J Respir Crit Care Med. 2001; 164: 1885-1889
        • Foreman MG
        • Mannino DM
        • Kamugisha L
        • Westney GE.
        Hospitalization for patients with sarcoidosis: 1979–2000.
        Sarcoidosis Vasc Diffuse Lung Dis. 2006; 23: 124-129
        • Swigris JJ
        • Olson AL
        • Huie TJ
        • Fernandez-Perez ER
        • Solomon J
        • Sprunger D
        • Brown KK.
        Sarcoidosis-related mortality in the United States from 1988 to 2007.
        Am J Respir Crit Care Med. 2011; 183: 1524-1530
        • Mirsaeidi M
        • Machado RF
        • Schraufnagel D
        • Sweiss NJ
        • Baughman RP.
        Racial difference in sarcoidosis mortality in the United States.
        Chest. 2015; 147: 438-449